These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 35219307)

  • 1. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
    Broughton EI; Gooden KM; Mycock KL; Rajkovic I; Taylor-Stokes G
    BMC Urol; 2022 Feb; 22(1):27. PubMed ID: 35219307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
    Kim HS; Seo HK
    Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
    Moussa M; Abou Chakra M; Shore ND; Papatsoris A; Farahat Y; O'Donnell MA
    Arch Ital Urol Androl; 2024 Mar; 96(1):12244. PubMed ID: 38502039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
    Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
    Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
    Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Okajima E; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
    World J Urol; 2024 Mar; 42(1):185. PubMed ID: 38512511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin-Unresponsive and Bacillus Calmette-Guérin-Exposed Nonmuscle-Invasive Bladder Cancer.
    Abou Chakra M; Shore ND; Dillon R; O'Donnell MA
    Urol Pract; 2024 Jan; 11(1):97-107. PubMed ID: 37903746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
    Kikuchi E; Ng CF; Kitamura H; Ku JH; Lee LS; Lin TP; Ng JYS; Nishiyama H; Poon DM; Kanesvaran R; Seo HK; Spiteri C; Tan EM; Tsai YS; Tran B
    Int J Urol; 2024 Jan; 31(1):32-38. PubMed ID: 37795933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
    Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
    Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
    Baek SW; Leem SH
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
    Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
    Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.
    Choo SH; Nishiyama H; Kitamura H; Chen CH; Pu YS; Lee HL; Jeong BC; Kim SI
    Int J Urol; 2019 Dec; 26(12):1121-1127. PubMed ID: 31512280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries.
    Palou-Redorta J; Rouprêt M; Gallagher JR; Heap K; Corbell C; Schwartz B
    World J Urol; 2014 Apr; 32(2):525-30. PubMed ID: 23907663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
    Loriot Y; Rouprêt M
    Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer Within a Large, Diverse Integrated Delivery System.
    Danforth KN; Sidell MA; Luong TQ; Yi DK; Yamamoto A; Kawatkar AA; Kim PH; Loo RK; Williams SG
    Urology; 2019 Sep; 131():93-103. PubMed ID: 31129191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances in BCG-unresponsive non-muscle invasive bladder cancer.
    Tse J; Singla N; Ghandour R; Lotan Y; Margulis V
    Expert Opin Investig Drugs; 2019 Sep; 28(9):757-770. PubMed ID: 31412742
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
    Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z
    Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.